{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-209044","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.921048+00:00","generated_at":"2026-05-14T22:28:31.839296+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Innoviva Q1 revenue $98M (+11% YoY); IST sales surge 37%; net income $186.6M","bullets":["Total revenue $98.0M, up 11% YoY; GSK royalty revenue $58.6M (down from $61.3M).","Net product sales $41.4M (+37% YoY); US sales $34.2M led by GIAPREZA $19.7M, XACDURO $11.6M.","Net income $186.6M ($2.52 EPS) driven by $191.2M favorable fair value change in equity investments, primarily Armata Pharmaceuticals.","Repurchased 971,066 shares for $20.4M in Q1 under $125M share repurchase program.","NUZOLVENCE (zoliflodacin) FDA-approved Dec 2025; availability expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-209044","json":"https://secwatch.observer/filing/0001193125-26-209044.json","markdown":"https://secwatch.observer/filing/0001193125-26-209044.md","text":"https://secwatch.observer/filing/0001193125-26-209044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000119312526209044/0001193125-26-209044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000119312526209044/d54063d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:28:31.839296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"94b85347de08a4b4da73acbb05d3501282f18ea7","claim":"Innoviva, Inc. reported first quarter ended March 31, 2026 results: revenue $98.0 million, net income $186.6 million, EPS $2.52 basic earnings per share.","evidence_excerpt":"and long-term shareholder value creation throughout variable market environments,” concluded Mr. Raifeld. Financial Highlights for the First Quarter of 2026 • Total revenue: $98.0 million, yielding 11% growth compared to $88.6 million for the first quarter 2025. • Royalty revenue: gross royalty revenue from Glaxo Group Limited (“GSK”) was $58.6 million, compared","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1080014/000119312526209044/0001193125-26-209044-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$98.0 million"},{"label":"Net income","value":"$186.6 million"},{"label":"EPS","value":"$2.52 basic earnings per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}